赛洛多辛(8 mg)单独用药对比联用Rotaprost(锯叶棕、异株荨麻、西葫芦)治疗良性前列腺增生的前瞻性观察性研究
DOI:
作者:
作者单位:

Central District Hospital, Outpatient Clinic, Kamenolomni 346480, Rostov Region, Russia

作者简介:

通讯作者:

中图分类号:

基金项目:


A Prospective, Observational Study of Use Combination Silodosin 8 mg Plus Serenoa Repens, Urtica Dioica, Cucurbita Pepo (Rotaprost) Compared With Silodosin 8 mg Alone in Treatment Patients with Benign Prostate Hyperplasia
Author:
Affiliation:

Central District Hospital, Outpatient Clinic, Kamenolomni 346480, Rostov Region, Russia

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    背景:良性前列腺增生(BPH)是造成老年男性下尿路症状(LUT)最常见的原因之一。目前,已有几种植物提取物用于治疗BPH引起的LUT。目的:本研究旨在探讨赛洛多辛 8 mg联合Rotaprost 530 mg[含锯叶棕(Serenoa Repens), 异株荨麻(Urtica Dioica), 西葫芦(Cucurbita Pepo)活性组分]复方用药,与二者分别单独使用,对LUTS/BPH患者的疗效差异。方法:自2020年6月至2021 年1月,总共招募了405例BPH症状的男性患者开展研究。对其中的389例患者进行为期6个月的跟踪随访。所有参与者均已提供书面知情同意书。这项前瞻性研究涵盖了对三个治疗组别的分析:第一组患者(n = 130)接受赛洛多辛8 mg和Rotaprost 530 mg联合用药[含锯叶棕干浸膏80 mg、异株荨麻干浸膏150 mg、西葫芦籽干浸膏200 mg、锌(以吡啶甲酸锌)0.105 mg和硒(以亚硒酸钠)22.5 μg];第二组患者(n =129)仅使用赛洛多辛8 mg;第三组患者(n = 130)仅使用Rotaprost 530 mg。通过国际前列腺症状评分(IPPS)总分值、前列腺特异性抗原(PSA)值、前列腺容积、排尿后残余尿量和尿液最大流速等参数与初始基态时相比产生的变化,测算最终疗效。设定P < 0.05为差异具有统计学意义。结果:随访期内,与第二组和第三组相比,第一组的IPSS、前列腺容积和尿液最大流速(Qmax)显著改善(P < 0.05)。6个月治疗期内,只有第一组的前列腺容积显著减少(P < 0.05)。三组均未出现严重不良反应。结论:联合用药相比单独用药,可显著减轻LUTS/BPH症状,降低Qmax和前列腺容积。而6个月单独使用530 mg Rotaprost治疗后,患者的PSA值至少降低了20.6%?25.7%。

    Abstract:

    Background: Benign prostatic hyperplasia (BPH) is one of the most common causes of lower urinary tract symptoms (LUTS) in older men. Nowadays, there are several plant extracts used for the treatment of LUTS due to BPH. Objective: The aim of this study is to compare the effect of combining silodosin 8 mg with Serenoa repens, Urtica dioica, Cucurbita pepo (Rotaprost 530 mg) compared to silodosin 8 mg and Rotaprost 530 mg alone in patients with LUTS/BPH.Methods: Four hundred five men with symptomatic BPH were recruited for the study from June 2020 to January 2021. Three hundred eighty-nine patients were followed up for 6 months. All participants provided written informed consent. This prospective study included analysis of three treatment groups: Group I patients(n = 130) received a combination of silodosin 8 mg and Rotaprost 530 mg (containing a dry extract of Serenoa repens 80 mg, a dry extract of Urtica dioica 150 mg, a dry extract of Cucurbita pepo seeds 200 mg, zinc (in the form of zinc picolinate) 0.105 mg, and selenium (as sodium selenite) 22.5 μg); the group II (n = 129) received silodosin 8 mg alone, and the group III (n = 130) received Rotaprost 530 mg alone. Outcomes were measured by changes from baseline in International Prostate Symptom Score (IPPS) total score, PSA value, prostate volume, residual urine after urination, and maximum flow rate. Statistical significance was set at P < 0.05. Results: In group I, IPSS, prostate volume, and maximum urinary flow rate (Qmax) improved significantly (P <0.05) compared with groups II and III during follow-up. Prostate volume in group I showed a significant decrease only during 6 months of therapy (P < 0.05). No serious adverse effects were registered in the three groups.Conclusion: Combination therapy with silodosin 8 mg significantly reduced LUTS/BPH, Qmax, and prostate volume compared with silodosin 8 mg alone. Rotaprost 530 mg can also reduce PSA by at least 20.6?25.7% after 6-months of treatment

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-11-18
  • 出版日期: